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probably	not.	only	1	appetite	stimulate,	
megestrol	acetate	oral	suspension	
(megace)	at	400	mg	or	800	mg	daily,	
has	been	studied	in	this	population.	the	
data	show	only	limited	benefit,	mixed	
outcomes,	and	potential	harm	(strength	
of	recommendation:	B,	based	on	small,	
randomized,	controlled	trials).	
Good advice for a common problem 
this	question	hits	home	for	me.	I	recently	
sat	down	with	the	husband,	and	main	
caregiver,	of	a	woman	with	advanced	
dementia.	the	woman	eats	very	little	and	
is	losing	weight	despite	her	husband’s	
great	efforts	at	encouraging	her	to	eat.	
under	the	care	of	another	physician,	she	
had	been	given	megestrol	acetate	and	
there	had	been	some	improvement.	Her	
visit	to	my	office	was	an	opportunity	to	
continue	an	ongoing	conversation	with	her	
husband	about	his	wife’s	overall	decline,	
her	advancing	dementia,	and	the	sorrow	
he	was	feeling	over	her	failing	health.	
	 Should	we	use	appetite	stimulants	in	
malnourished	elderly	patients?	“probably	
not.”	that	is	a	good	place	to	start	to	
avoid	harm	to	our	most	frail,	declining,	
elderly	patients	for	whom	we	care.	that	
leaves	open	flexibility	to	patient,	family,	
and	caregiver	preferences,	but	reminds	us	
that	the	most	important	part	of	caring	for	
these	patients	and	their	families	is	clear,	
compassionate	communication	regarding	
goals	and	expectations.	
 
Kayleen P. Papin, MD
medical	College	of	Wisconsin,	milwaukee
z 	Evidence summary
Although a number of studies have 
evaluated various appetite stimu-
lants—megestrol, dronabinol (Marinol), 
cyproheptadine (Periactin), thalidomide 
(Thalomid), pentoxifylline (Pentoxil/
Trental), nandrolone decanoate (Deca-
Durabolin), oxandrolone (Oxandrin), 
and corticosteroids—in patients with 
AIDS, anorexia cachexia syndrome, and 
advanced cancer, only megestrol has been 
studied in malnourished elderly patients. 
Two studies, mixed results
One placebo-controlled randomized 
clinical trial studied 45 malnourished 
patients who were recently discharged 
from an acute care hospital to a nursing 
home. The patients (predominately fe-
male, with a mean age of 83) were ran-
domized into 4 treatment arms (placebo 
or megestrol 200 mg, 400 mg, or 800 
mg daily) and followed for 63 days. 
Only those receiving megestrol (400 
mg or 800 mg daily) demonstrated a sta-
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tistically significant increase in patient 
appetite and a dose-responsive increase 
in prealbumin level at the 20 day interim 
analysis (7.5 and 9.0 mg/dL, respectful-
ly). But at the final assessment (63 days), 
only the 400-mg dose maintained a sta-
tistically significant increase in prealbu-
min over placebo. However, there was 
no significant improvement in serum 
albumin or clinical endpoints (weight, 
functional status, or health-related qual-
ity of life).1 
In contrast, an earlier Veterans Ad-
ministration (and predominantly male) 
study showed 13/21 of those treated with 
megestrol (800 mg daily for 12 weeks) 
noted weight gain (≥4 lb sustained at 
3 months post-treatment), compared 
with 5/23 of those receiving placebo 
(number needed to treat [NNT]=2.5).2 
Of note, only 9/26 patients had sus-
tained weight gain in the megestrol 
group at the 12-month endpoint post-
treatment, comparable with 7/25 in the 
placebo group. 
Some small, but statistically signifi-
cant, score improvements were noted 
during the treatment period in appe-
tite and enjoyment of life; however, no 
differences were noted in scores on the 
more widely accepted Geriatric Depres-
sion Scale. 
Adverse effects
As in all therapeutic interventions, ben-
efit must be balanced against risk. The 
Megace ES package insert notes the 
following potential adverse effects: di-
arrhea, cardiomyopathy, palpitation, 
hepatomegaly, leukopenia, edema, pares-
thesia, confusion, convulsion, depression, 
neuropathy, hypesthesia and abnormal 
thinking, thrombophlebitis, pulmonary 
embolism, and glucose intolerance.3 
To date, the prevalence rates of 
these potential adverse effects have only 
been studied in patients with AIDS. No 
data reflecting potential rates in elderly 
patients have been published. 
Recommendations from others
The American Geriatric Society4 made 
3 comments on appetite stimulation: 
1.  There are no FDA-approved 
drugs available for the promotion 
of weight gain in older adults. 
2.  A minority of patients receiving 
mirtazapine report appetite stim-
ulation and weight gain. 
3.  All drugs used for appetite have 
substantial potential adverse 
events.
We found only 1 national guide-
line on this topic: Unintentional Weight 
Loss in the Elderly from the University 
of Texas School of Nursing.5 The guide-
line indicates that drugs should not be 
used as first-line intervention in the el-
derly, as there has been inadequate test-
ing in this population. Benefits are re-
stricted to small weight gains without 
indication of decreased morbidity or 
mortality, improved quality of life, or 
improved functional ability. n
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The only national 
guideline on 
weight loss in the 
elderly does not 
recommend  
medication as the 
first-line treatment
